The Impact of Scaffold, Linker, Homogeneity and Payload Selection on the Efficacy and Tolerability of Anti-Tubulin ADCs
Results From the Phase 1 Dose Escalation Study of XMT‑1592, a NaPi2b‑Directed Dolasynthen ADC
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer
April, 2022
Site Specific Dolasynthen ADCs Demonstrate Consistent Exposure Across a Wide Range of Drug-To-Antibody Ratios
October, 2021
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
April, 2021
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
June, 2020
Mersana’s Innovative ADC Platforms – World ADC Summit 2019
October 2019